July 29 (Reuters) - AstraZeneca ( AZN ) beat

second-quarter earnings expectations on Tuesday, helped by

strong sales of key cancer, heart and kidney disease drugs, but

maintained its full-year forecast as pricing pressures and

global trade risks remain challenges.

The company hopes to move on from scandals in China, after

indicating that any impact from probes in its second-biggest

market would be minor, and focus on growing its U.S. footprint

and drug pipeline to reach $80 billion in annual revenue by

2030.

AstraZeneca ( AZN ) said last week it plans to spend $50 billion to

expand manufacturing and research capabilities in the United

States by 2030, the latest drugmaker to ramp up investments in

the country in response to President Donald Trump's tariff

threat.

The Anglo-Swedish drugmaker is counting on a wave of

expected launches of 20 new medicines and its U.S. expansion to

reach its $80 billion annual revenue target by the end of this

decade.

AstraZeneca ( AZN ), the UK's largest listed company by market

value, reported revenue growth of 11% to $14.46 billion for the

three-month period ended June at constant currency rates, with

core earnings of $2.17 per share.

"Our strong momentum in revenue growth continued through the

first half of the year and the delivery from our broad and

diverse pipeline has been excellent," CEO Pascal Soriot said in

a statement.

Analysts were expecting $14.15 billion in revenue and $2.16

in earnings per share for the second quarter, according to a

company-provided consensus.

(Reporting by Pushkala Aripaka and Unnamalai L in Bengaluru,

and Maggie Fick in London; Editing by Subhranshu Sahu)